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DOSE CALCULATIONS FOR [131I] META-IODOBENZYLGUANIDINE-
INDUCED BYSTANDER EFFECTS
M. D. Gow1, C. B. Seymour1, M. Boyd2, R. J. Mairs2,3, W. V. Prestiwch1, and C. E.
Mothersill1  1Medical Physics and Applied Radiation Sciences Department,
McMaster University, Hamilton, Ontario, Canada L8S 4K1; 2Targeted Therapy
Group, Division of Cancer Science and Molecular Pathology, Glasgow University,
Cancer Research United Kingdom Beatson Laboratories, Glasgow, United
Kingdom; 3Department of Child Health, Yorkhill Hospital, Glasgow, United
Kingdom
 Targeted radiotherapy is a potentially useful treatment for some cancers and may be
potentiated by bystander effects. However, without estimation of absorbed dose, it is diffi-
cult to compare the effects with conventional external radiation treatment. Methods:
Using the Vynckier – Wambersie dose point kernel, a model for dose rate evaluation was
created allowing for calculation of absorbed dose values to two cell lines transfected with
the noradrenaline transporter (NAT) gene and treated with [131I]MIBG. Results: The
mean doses required to decrease surviving fractions of UVW/NAT and EJ138/NAT cells,
which received medium from [131I]MIBG-treated cells, to 25 - 30% were 1.6 and 1.7 Gy
respectively. The maximum mean dose rates achieved during [131I]MIBG treatment were
0.09 - 0.75 Gy/h for UVW/NAT and 0.07 - 0.78 Gy/h for EJ138/NAT. These were signifi-
cantly lower than the external beam gamma radiation dose rate of 15 Gy/h. In the case of
control lines which were incapable of [131I]MIBG uptake the mean absorbed doses fol-
lowing radiopharmaceutical were 0.03 - 0.23 Gy for UVW and 0.03 - 0.32 Gy for EJ138.
Conclusion: [131I]MIBG treatment for ICCM production elicited a bystander dose-
response profile similar to that generated by external beam gamma irradiation but with
significantly greater cell death.
Key words: radiation bystander effect, MIBG, gene therapy, targeted radiotherapy, Vynckier -
Wambersie
1. INTRODUCTION
Radiation therapy as a primary or adjunct procedure is used in
approximately 60% of all cancer patients (Perez and Brady 1998). The
purpose of this treatment is to deliver a lethal dose of radiation to a
tumour site while sparing as much healthy tissue as possible. Targeted
radiotherapy seeks to deliver a lethal dose of radiation to tumours while
minimizing damage to normal organs (Boyd et al. 2004, Kufe and
Weichselbaum 2003, Mitrofanova et al. 2006, Mairs and Boyd 2003).
Radiolabelled [131I] meta-iodobenzylguanidine (MIBG), a low-LET β-par-
Address correspondence to Dr. Carmel E. Mothersill, Medical Physics and Applied
Radiation Sciences Department, McMaster University, 1280 Main Street West, Hamilton,
Ontario, Canada L8S 4K1. Tel: + 1.905.525.9140 x26227; Fax: + 1.905.522.5982; Email: moth-
ers@mcmaster.ca
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ticle emitter, is used for the diagnosis and treatment of patients with
tumours derived from the neural crest (Cunningham et al. 2000, Mairs
1999). An analog of adrenergic neuron blockers (Wieland et al. 1980),
MIBG is actively taken up via the noradrenaline transporter (NAT) – a
high affinity, saturable and ATPase-dependent mechanism (Jacques et al.
1984, Mairs and Boyd 2008).
Heterogeneous uptake of [131I]MIBG by tumours is an obstacle to a
cure. This may be overcome by cross-fire irradiation of untargeted cells
from neighbouring cells which have concentrated the radiopharmaceuti-
cal. However, collateral damage may also derive from radiation-induced
biological bystander effects (RIBBE). RIBBE induced by [131I]MIBG were
examined by measurement of surviving fraction of recipient cells follow-
ing irradiated-cell conditioned medium (ICCM) transfer (Boyd et al.
2006), originally developed by Mothersill and Seymour (1997). These
results indicate substantial bystander cell kill. Unfortunately the survival
data were presented as a function of activity concentration rather than
absorbed dose. This causes difficulty in comparing RIBBE capability with
previous estimates.
Therefore, this work sought to develop a dosimetric model for calcu-
lating absorbed dose to donor cells used in the creation of ICCM follow-
ing treatment with [131I]MIBG. This was accomplished through utiliza-
tion of the Vynckier-Wambersie point source dose distribution (Vynckier
and Wambersie 1982) applied to the appropriate geometry. Two separate
models were developed and compared to determine the most computa-
tionally efficient method to perform calculation of absorbed dose over a
range of applied activity concentration. For UVW and EJ138 cell lines
used by Boyd et al. (2006), dose rate and absorbed values were calculated
for each activity concentration applied. Following this, a re-examination
of survival fraction data was undertaken comparing [131I]MIBG and
external beam radiation with respect to bystander cell death response.
2. MATERIALS AND METHODS
Experimental procedures utilized for assessment of recipient
bystander cell death (i.e. surviving fraction) following treatment with
ICCM generated from donor cell exposure to [131I]MIBG were previous-
ly described in detail (Boyd et al. 2006).
2.1 Cell lines
Cell line hosts utilized were the UVW human glioma cell line (Boyd
et al. 2004) and the EJ138 human bladder carcinoma cell line (Fullerton
et al. 2005) and were maintained in 75-cm2 flasks containing Eagle’s MEM
with 25 mmol/L N-(2-hydroxy-ethyl)piperazine-N9-(2-ethanesulfonic
acid) buffer and Earle’s Salt, supplemented with 10% (v/v) fetal bovine
serum, penicillin/streptomycin (100 U/mL), fungizone (2 mg/mL),
M.D. Gow and others
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L-glutamine (2 mmol/L), and nonessential amino acids (0.1 mmol/L).
Cells were cultured at 37°C in a 5% CO2 atmosphere. As UVW and EJ138
do not naturally express NAT required for active MIBG uptake, both cell
lines were transfected according to previously described methods
(Fullerton et al. 2005, Boyd et al. 1999). Cell size was determined using a
Model TT Cell Counter and Analyzer System (Scharfe System, RJM Sales,
NJ, USA). More than 10,000 cells were counted per measurement result-
ing in a mean ± SD diameter of 16.5 ± 0.9 µm and 12.8 ± 0.7 µm for UVW
and EJ138 respectively. The doubling time was 18 hours for UVW and
17.5 hours for EJ138.
2.2 Uptake and Medium Transfer Experiments
Results of previous experiments indicated the administered and accu-
mulated activity as a percentage of the activity in the incubation medium
was 31.4% ± 3.7% for UVW/NAT cells and 21.4% ± 1.9% for EJ138/NAT
cells with a linear relation between activity accumulated and administered
(Boyd et al. 2006). The medium transfer technique has been described in
detail in (Mothersill and Seymour 1997). Cells were initially seeded at 2
× 105 cells per 25-cm2 flask in 10 ml of complete medium and incubated
for 24 h before irradiation. These cultures were 65 ± 5% confluent.
Irradiated cells which produced conditioned medium (ICCM) were
labelled “donors” while cells which received ICCM and not directly irra-
diated where labelled “recipients”. Irradiation of donor cells occurred by
one of two methods:
1. Donor cells were irradiated by way of a 60Co γ-ray source at a dose rate
of 15 Gy/h through a range of doses from 0 to 9 Gy. Immediately fol-
lowing treatment, donor cells were returned to the incubator and
maintained at 37°C and 5% CO2 for one hour followed by removal of
the medium (regardless of dose) which was passed through a 0.22-µm
to ensure that no cell was present in the transferred medium (Moth-
ersill and Seymour 1997). Medium was removed from recipient cells
and replaced with the filtered ICCM. These recipient cells were then
incubated and eventually seeded for clonogenic assay (Boyd et al.
2006). This experiment was performed 6 times in triplicate.
2. Donor cell medium was removed on the day of exposure and replaced
with 1 ml of fresh medium. Cells were treated with activity concentra-
tions of 0 to 11 MBq/ml of [131I]MIBG for 2 h as described previously
(Boyd et al. 2004, Fullerton et al. 2005, Boyd et al. 1999, Mairs et al.
1995). This portion of the experiment was termed the “Uptake”
phase. After 2 h, the donor medium was removed and cells are washed
with PBS to eliminate unincorporated radiopharmaceutical. Five mil-
lilitres of fresh medium was then applied and the donor cells were
placed back in the incubator for 1 h to allow for bystander factors to
Dose calculations for [131I]MIBG induced RIBBE
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accumulate and yield an ICCM. This portion of the experiment was
termed the “Accumulation” phase. Egressed activity from the donor
cells was ≤ 1% of activity added for all concentrations during this
phase and activity controls indicated no significant cell death from
such activity levels (Boyd et al. 2006). Following 1 h, ICCM was re-
moved, passed through a 0.22-µm filter, and added to recipient cells
for which the medium had been discarded. These cells were then
treated identically to gamma-irradiated cells described above.
A set of cultures was used to determine whether bystander effects
were induced in untransfected UVW and EJ138 donor cells undergoing
identical [131I]MIBG treatment as described for the NAT gene-transfect-
ed cells. NAT-negative cells were labelled “parental”. ICCM from these
types was applied to both NAT gene-transfected and untransfected cells.
2.3 Dosimetry Model
When determining the dose to the donor cells used to create the
ICCM, dose contributions occurring during both the uptake and accu-
mulation phases of [131I]MIBG treatment need be considered. It is
unknown which dose initiates the bystander responses leading to cyto-
toxic factor accumulation when fresh medium is applied. Previous exper-
iments have illustrated a linear accumulation of MIBG for NAT-express-
ing cell types during the first two hours of exposure (Armour et al. 1994).
This coupled with the ≤ 1% egressed activity seen in both UVW/NAT and
EJ138/NAT after accumulation (Boyd et al. 2006) provides a dose rate
function, Ḋ(t), as illustrated in Figure 1.
Upon application of [131I]MIBG-enhanced medium, the assumption
is an instantaneous, homogenous, static mixture uniformly covering all
cells with an initial dose rate of Ḋup (Gy/h). As donors actively uptake
[131I]MIBG over 2 h, dose rate increases linearly up to a maximum dose
rate of Ḋacc (Gy/h) when the radioactive medium is removed and cells are
washed with PBS. When fresh medium is added to allow bystander factors
to accrue, the dose rate remains effectively constant at Ḋacc due to the
negligible amount of egress. Therefore, in order to find the total
absorbed dose to the donor cells used to create the ICCM, integration is
performed on the function presented in Equation 1 1:
(1)
where Ḋup and Ḋacc are the average initial dose rates upon initiation of the
uptake and accumulation phases respectively.
To calculate Ḋup and Ḋacc, the Vynckier-Wambersie point-source dose
distribution function (point kernel) is utilized (Vynckier and Wambersie
1982, Vynckier and Wambersie 1986):
M.D. Gow and others
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(2)
with [ ] ≡ 0 for ρvx ≥ c and J(x) ≡ 0 for ρvx ≥ f where:
J(x) is the absorbed dose rate at a distance x (in cm) from a point
source (Gy/MBq⋅h)
v is an apparent absorption coefficient (in cm2/g). Within the maximum
β-energy range , this value can be expressed
as a function of (14): 
ρ is the density of the homogenous medium
c is a dimensionless parameter that provides a value for the first term
inside the curly brackets to become and remain 0; this parameter was
originally defined by Loevinger (Loevinger, Japha and Brownwell,
1956) as:
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FIGURE 1. Irradiation to donor cells used in the production of irradiated-cell conditioned medium
(ICCM) occurs in two phases: i) an uptake phase during which [131I]MIBG is taken up by NAT trans-
fected cells and ii) an accumulation phase where fresh medium is applied and bystander factors
accrue creating the ICCM. The total dose can be determined through simple integration of the
above function. 
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B is a normalization constant evaluated for the requirement that the
energy emitted by the point source is equal to the energy absorbed
by an infinitely large sphere. It is obtained via:
where
and Eβavg is the average β-particle energy (in MeV)
f is a dimensionless parameter where f/ρx represents the distance at
which the β dose is required to be zero. Within the energy range
, this value can be described as a function of
Eβmax (Vynckier and Wambersie 1986): 
The Vynckier-Wambersie kernel can be integrated over a number of
simple geometries to model a variety of source conditions. Here, two ver-
sions of the Vynckier-Wambersie kernel are applied; a) during uptake, a
plane of infinite extent and finite thickness and b) during accumulation,
a series of planes of infinite extent that are infinitely thin. The Vynckier-
Wambersie kernel can be modelled as infinite in extent, with < 5% cor-
rection for radius, provided that the radius of the plane is ≥ 0.5Rmax, the
continuous slowing-down approximation (CSDA) range of the most
energetic β-particle (The International Commission on Radiation Units
and Measurements, 2004). For 131I, Eβmax is 0.61 MeV resulting in an
approximate CSDA maximum range of 0.227 cm. Under these condi-
tions, the Vynckier-Wambersie plane kernel can be modelled with infi-
nite extent down to a surface area covering 0.04 cm2. With donor cell
treatment occurring in 65% ± 5% confluent 25 cm2 flasks, the true cov-
erage area is 16.25 cm ± 1.25 cm. Thus, under these conditions, one can
simply apply an identical transformation to all donor flasks, modelling a
typical confluent flask as a singular cylindrical slab of cells as illustrated
in Figure 2.
As the Vynckier-Wambersie kernel is a function of distance from the
source, in order to calculate the dose during both the uptake and accu-
mulation phases, it is required that the thickness of the cells upon adher-
ence to the flask be determined (i.e. determine the thickness of the slab).
To accomplish this, it is noted that 2 × 105 cells were plated 24h prior to
[131I]MIBG treatment at which point donor flasks were 65% ± 5% con-
fluent in 25 cm2 flasks. The cell lines have doubling times of 18 h and 17.5
h for UVW and EJ138 respectively. Thus, the resulting the number of cells
present at the time of treatment (C) via:
ρ βf = 0.269 x(E )max
1.31
0.5 MeV < E < 3.5 MeV
maxβ
 = 3c  - (c  - 1)e + (3 + f)e  - 4e-1 2 2
1 - f 1 - (f/2)α ( ) ( )
ρ α× ⋅βB = (4.6 10 ) v (E ) in (Gy/MBq h)
2 2 3
avg
M.D. Gow and others
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(3)
where C0 is the number of cells plated and DT is the doubling time of the
cell line used. In addition, volume is conserved upon adhesion to the
flask relative to the volume of a cell in suspension. Therefore, with knowl-
edge of the diameter of the UVW and EJ138 cell lines (16.5 ± 0.9 µm and
12.8 ± 0.7 µm respectively), the total volume for the number of donor
cells after 24 h (calculated via Eq. 3) in suspension is calculated via:
(4)
and determine the thickness of the cellular slab via:
(5)
where Δ is the half thickness of the cellular slab. Given the experimental
conditions in (Boyd et al. 2006), the resultant cellular slab thickness was
calculated as
(7.3 ± 0.9) × 10–5 cm for UVW and (3.5 ± 0.4) × 10–5 cm for EJ138.
π ( )• •
⎡
⎣
⎢
⎤
⎦
⎥V  = C
4
3
0.5 Cell
tot diam
3
= Δ =
•
thickness 2
V
(Total Flask Growth Surface Area
% Confluence @ treatment)
tot
C = C e
0
(time)ln2
DT
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FIGURE 2. Schematic representation of cellular distribution in donor flasks used in irradiated-cell
conditioned medium (ICCM). (A) represents an approximation of the actual distribution and (B)
represents the same cellular distribution modelled as an aggregation of infinite Vynckier –
Wambersie cellular slabs. Since the dose to the entire cellular distribution in (B) is the sum of infi-
nite Vynckier – Wambersie cellular slabs, for simplicity, a single transformation to donor cells is
applied in (A) resulting in a single cylindrical slab of cells (C). 
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2.4 Dose Rate Calculation: Uptake Phase
As per Figure 1 and Eq. 1, the aim is to calculate the initial dose rate,
Ḋup, upon application of radiopharmaceutical-enhanced medium to
donor cells. This scenario is illustrated in Figure 3.
During donor treatment with [131I]MIBG, radiopharmaceutical was
added to 1 ml of fresh medium during the 2 h allotted for uptake. First,
observe that the thickness of this 1 ml of radioactive medium at a density
equivalent to water (i.e. 1 g/cm3) covering a 25 cm2 growth area results is
simply 0.04 cm. The density of the radioactive medium and cellular slab
is equivalent. The dose rate at a given distance, x, from our source is
dependent on the extent (i.e. diameter), d, of the source as well as its
thickness, h, resulting in the function Ḋup(x,h,d). From (Vynckier and
Wambersie 1986), a source of infinite extent and thickness, h, greater
than the maximum range of the most energetic β-particle, the dose rate
(in Gy/h) is given by:
(6)
with [ ] ≡ 0 for ρvx ≥ c and Ḋ(x,∞,∞) ≡ 0 for ρvx ≥ f.
M.D. Gow and others
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FIGURE 3. Illustration of cell and medium distribution at the onset of the uptake phase immediate-
ly following application of radiopharmaceutical. 
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Additionally, it is noted that Ḋ(0,∞,∞) represents the dose rate (in
Gy/h) at the edge of an infinite medium. This is equivalent to the dose
rate of a semi-infinite medium or half the dose rate of an infinite medi-
um and is expressed by:
(7)
where am is the mass activity concentration (MBq/g) and the average β-
particle energy in MeV. In our scenario, with our source of unit density,
the value for activity is simply the activity concentration (in MBq/ml =
MBq/g = MBq/cm3) administered divided by the number of millilitres of
medium (in our case 1 ml). Additionally, since it is assumed that an
instant, homogenous, static mixture upon application, radioactive medi-
um covering growth area with no cell present does not contribute dose to
the donor cells as this space is effectively located at “infinity”. Therefore,
one can adjust for cellular confluence levels and perform a simple modi-
fication to Eq. 7 as follows:
(8)
where Aconc_up = (Aadmin)(% Confluence)
With 131I having a maximum CSDA range of 0.226 cm, five times
greater than the thickness of the 1 ml of radioactive medium, the thick-
ness of the source cannot be neglected. From simple geometric consid-
erations, it is determined that (Vynckier and Wambersie 1986):
(9)
Utilizing Eq. 6, 8, and 9, Ḋup was calculated at x = 0 and 2Δ for h = 0.04
cm. The results were averaged to determine the mean dose rate to the
slab upon initial application of the [131I]MIBG-enhanced medium:
(10)
Due to the small magnitude of the cellular slab thickness, there was <
2% difference in Ḋup(0,0.04,∞) and Ḋup(2Δ,0.04,∞) resulting in a < 1%
difference between the calculated mean Ḋup value and the dose rate at
any cellular distance from the source.
2.5 Dose Rate Calculation: Accumulation Phase
Two separate models were developed for comparison and computa-
tional efficiency evaluation. The fundamental difference between the
models lies in the manner in which the source is distributed within the
slab; homogenously or in discrete planes.
{ }∞ ∞ ∞ ∞⎡⎣ ⎤⎦ Δ ∞ ∞ Δ ∞ ∞⎡⎣ ⎤⎦D  = D(0, , ) - D(0.04, , )  + D(2 , , ) - D(2 +0.04, , ) / 2up    
( ) ( ) ( )= ∞ ∞ − ∞ ∞D x,h,d D x, , D x+h, ,up  
D(0, , )  = 0.288(A )E
conc_up avg
 ∞ ∞ β
D(0, , )  = 0.288a E
m avg
 ∞ ∞ β
Dose calculations for [131I]MIBG induced RIBBE
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Method #1: “Homogenous-Slab”
During the 1 h accumulation phase, while bystander factors are
allowed to accrue in 5 ml of fresh medium, it is assumed that the
[131I]MIBG taken up by the cells is homogenously distributed within the
cellular slab with an activity concentration, Aconc_acc (in MBq/cm
3). Aconc_acc
is dependent on several factors including cellular confluence, (for analo-
gous reasoning as in the uptake phase), radiopharmaceutical uptake per-
centage for the cell line, as well as the volume of the cellular slab:
(11)
The source is split into a bunch of infinitely thin planes of infinite
extent with surface activity, As, given by Aconc_acc dx′ (in MBq/cm
2) (see
Figure 4). The dose rate contribution from a single plane is dḊ = Aconc_acc
K(x-x′,0,∞)dx′ where K(x-x′,0,∞) is the Vynckier –Wambersie dose rate
kernel for an infinitely thin, infinite extent plane. This expression is given
by (Vynckier and Wambersie 1986, The International Commission on
Radiation Units and Measurements 2004):
(12)
Δ
A  = 
(A )(% Uptake)
(25 cm )( % Confluence)(2 )conc_acc
conc_up
2
α
ρ
∞ • •
⎛
⎝
⎜
⎞
⎠
⎟
⎡
⎣
⎢
⎢
⎤
⎦
⎥
⎥
⎧
⎨
⎪
⎩⎪
⎫
⎬
⎪
⎭⎪
ρ
ρ
ρ⎛
⎝
⎜
⎞
⎠
⎟
⎛
⎝
⎜
⎞
⎠
⎟
K(x-x',0, ) = 0.288 v
c 1 + ln
v(x-x')
c
 - e  + e  - 2e  + e
1 - 
v(x-x')
c (1 - v(x-x'))
1 - 
v(x-x')
c
 - 
f
2 (1 - f)
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FIGURE 4. Illustration of Method #1 radiopharmaceutical modelling during the accumulation
phase. The source is considered split into a bunch of infinite thin disks of surface activity As = Aconc_acc
dx′ (MBq/cm2). For a point x a distance x-x′ from the source, the dose rate contribution is given by
dḊ = Aconc_acc K(x-x′,0,∞)dx′ where K(x-x′,0,∞) is the Vynckier–Wambersie dose rate kernel for a
plane that is infinitely thin and of infinite extent. 
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To determine the expression for the total dose rate to the cellular slab
during the accumulation, integrate over the range x = 0 to 2Δ:
(13)
The kernel is actually a function of the distance from the plane to the
point of measurement (i.e. |x-x′|). To compensate for this, a change of
variables to u = x-x′ is made resulting in:
(14)
Then, let u = |v| providing:
(15)
Lastly, the average dose rate to the slab, Ḋacc, is obtained by determin-
ing the average dose rate from Eq. 13 over the entire thickness of the slab:
(16)
Method #2: “Multi-isoplane”
Due to the relative thinness of the cells upon adherence to the cul-
ture flasks, a second model was created with the aim of improving on the
computational efficiency of the model calculations during the accumula-
tion phase while maintaining the same degree of precision as Method #1.
To do this, two paradigms were created in which the activity was evenly
distributed into isolated, homogenous planes and dose rates were com-
puted at various positions within the slab (see Figure 5). Paradigm (A)
calculates the dose rate at positions x = 0, Δ, and 2Δ with source planes at
x = 0.5Δ and 1.5Δ while paradigm (B) calculates the dose rate at x = 0.5Δ
and 1.5Δ with source planes at positions x = 0, Δ, and 2Δ. The surface
activity of given plane is provided by:
(17)
with,
(18)
The dose rate at a various positions x1-5 are given by:
A   1
2
A  + 1
2
A  for Paradigm (A)
 1
3
A  + 1
3
A  + 1
3
A  for Paradigm (B)
tot_acc surf_acc surf_acc
surf_acc surf_acc surf_acc
=
=
A
(A )(% Uptake)
(25 cm )(% Confluence)surf_acc
conc_up
2
=
D(x) A K(v,0, )dv + K(v,0, )dv
x
conc_acc 0
2
0
x  ∫ ∫= ∞ ∞⎡⎣⎢
⎤
⎦⎥
Δ−
∫= ∞=
= Δ
D(x) A K(x-x',0, )dx'
conc_acc x' 0
x' 2 
D(x)=A K(u,0, )du + K(u,0, )du
conc_acc x-2
0
0
x  ∫ ∫∞ ∞⎡⎣⎢
⎤
⎦⎥Δ
Dose calculations for [131I]MIBG induced RIBBE
11
11
Gow et al.: Dose calculations for [131I]MIBG induced RIBBE
Published by ScholarWorks@UMass Amherst, 2014
(19)
(20)
(21)
The final dose rate during the accumulation phase using Method #2 is:
(22)
The results of Eq. 10 and either 16 or 22 were substituted into Eq. 1
in order to obtain the total dose to the donor cells used to create the
ICCM for recipient cell treatment.
D(x ) = 2 ( 1
3
A )K(0.5 ,0, ) + ( 1
3
A )K(1.5 ,0, ) = D(x ) 
4 surf_acc surf_acc 5
 • Δ ∞ Δ ∞
D(x ) = 2 ( 1
2
A )K(0.5 ,0, )
2 surf_acc
 • Δ ∞
D(x ) = ( 1
2
A )K(1.5 ,0, ) + ( 1
2
A )K(0.5 ,0, ) = D(x ) 
1 surf_acc surf_acc 3
 Δ ∞ Δ ∞
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FIGURE 5. Illustration of Method #2 radiopharmaceutical modelling during the accumulation
phase. The dose rate along five separate planes is calculated via one of two paradigms: (A) For equal-
ly distributed activity in two infinite planes located at x = 0.5Δ and 1.5Δ, calculate Ḋ at x = 0, Δ, and
2Δ (Paradigm #1). (B) For equally distributed activity in three infinite planes located at x = 0, Δ, and
2Δ, calculate Ḋ at x = 0.5Δ and 1.5Δ. The average dose rate to the slab, Ḋacc, is calculated as the aver-
age dose rate from these five locations. 
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2.6 Software and Statistics
All modelling and calculations were performed using MATLAB 7.9.0
(R2009b; 32-bit; The Mathworks). Analytical integration for the
“homogenous-slab” model was performed leveraging either the MATLAB
Symbolic Toolbox (ver. 5.3) MuPAD engine or the Maple 13 (Maplesoft)
symbolic engine. Two separate MATLAB M-file programs were created: a)
comparing the “homogenous-slab” and “multi-isoplane” models during
accumulation phase for dose rate results and computation time; and b)
the complete dosimetry model allowing automatic calculation of cell slab
thickness, dose rates during uptake and accumulation phases (using
“multi-isoplane” model), and total ICCM dose following user input of the
various experimental parameters outlined in Boyd et al.’s original work
(Boyd et al. 2006). Both of these programs can be run within the MAT-
LAB environment with output for the dosimetry model being directed to
either the terminal or a variety of Microsoft Excel file formats. In addition
to this, a standalone Microsoft Windows operating system (OS) applica-
tion was created for the dosimetry model via utilization of MATLAB’s
‘deploytool’ package and MATLAB compiler (ver. 4.11). This standalone
executable was developed to run on any Windows-based host OS, inde-
pendent of any MATLAB installation, after a one-time installation of the
MATLAB Compiler Runtime libraries (ver. 7.11) delivered with the exe-
cutable. This application was tested successfully under Windows XP (NT
5.1; SP 3; 32-bit) and Windows 7 (NT 6.1; SP 1; 64-bit) operating systems.
All modelling and calculations were performed on the same machine
containing an Intel Core 2 Duo T5870 processor at 2.00 GHz (L1 cache
= 64 KB; L2 cache = 2 MB) with 3.0 GB of RAM (SODIMM DDR2 at 667
MHz) running a Windows 7 (SP 1) OS.
Particle range data was obtained through the ESTAR program devel-
oped by the National Institute of Standards and Technology (NIST)
Physical Measurement Laboratory utilizing water as the medium.
Recipient cell surviving fractions is presented as the mean ± standard
deviation (SD) with significance determined via student’s t test with con-
fidence value p = 0.05. Uncertainty in dose was determined through tra-
ditional propagation uncertainty methods (i.e. “square root of the sum of
squares”) from mean ± minimum/maximum dose rate values obtained
from optimization of values for cell slab thickness, donor flask conflu-
ence, and [131I]MIBG uptake percentage (e.g. maximum dose rate dur-
ing the accumulation phase for Method #1 occurs for maximum uptake
percentage for the smallest slab thickness and donor flask confluence).
Dose calculations for [131I]MIBG induced RIBBE
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3. RESULTS
Comparison of dose rate values and computational performance between
“homogenous-slab” and “multi-isoplane” modelling of dose rate during
accumulation phase
As an approximated method had been developed (“multi-isoplane”
source; Method #2) to model the dose rate to donor cells during ICCM
production (“Accumulation Phase”), comparison of the dose rate calcu-
lations versus the “homogenous-slab” source (Method #1) was undertak-
en in order to determine the optimal methodology to employ. It was
anticipated that both methods would yield answers that were in agree-
ment and the method that produced the least amount of computational
overhead would be utilized. For an activity concentration of 1 MBq/ml
and experimental parameters associated with UVW/NAT donor cells, the
average dose rate results for each method as well as computation time
required are shown in Table 1.
As would be expected, both MATLAB’s inherent MuPAD symbolic
engine and Maple’s symbolic engine yielded identical dose rate results via
the “homogenous-slab source” model. The Maple symbolic engine great-
ly outperformed MuPAD in computational efficiency by performing the
identical calculation over 7 times faster. By comparison, our “multi-iso-
plane” model yielded an answer well within agreement of the Method #1
answer, with equivalent relative uncertainty. In addition, this method was
over 185 times more efficient than even Maple’s symbolic engine. These
results directed the use of the “multi-isoplane” method in the further
examination of complete survival fraction data from (Boyd et al. 2006).
Calculation of dose for [131I]MIBG ICCM and corresponding examination
of UVW/NAT and EJ138/NAT recipient cell survival curves
Utilizing the “multi-isoplane” method during the ICCM “accumula-
tion” phase coupled with the associated Vynckier-Wambersie derived
expression for a finite-thick, β-emitting slab during the uptake phase,
dose rates and overall absorbed doses to UVW and EJ138 were calculated.
M.D. Gow and others
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TABLE 1. Comparison of modelling methodologies used to calculate dose rate during ICCM pro-
duction. 
Avg. Dose Rate during ICCM Avg. Computation Time 
production (Gy/h) per Calculationa (s)
Method #1a (MuPAD) 0.0999 ± (0.033/0.025) 30.84 ± 0.41
Method #1b (Maple) 0.0999 ± (0.033/0.025) 3.98 ± 0.54
Method #2 0.0937 ± (0.031/0.024) 0.0215 ± 0.0021
a Calculations measured over 9 independent trials (n = 9) after memory cleared and represented
as total time to calculate dose rate and uncertainties ± SD.
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First, the cellular slab thickness was determined for each cell line, result-
ing in values of 0.73 µm ± 0.09 µm for UVW and 0.35 µm ± 0.04 µm for
EJ138. Next, activity concentrations of [131I]MIBG ranging from 1-8
MBq/ml and 1 - 11 MBq/ml for UVW and EJ138 respectively were uti-
lized to calculate the dose rate during both phases. Mean dose rates
ranged from 0.015 to 0.116 Gy/h for UVW and 0.014 to 0.161 Gy/h for
EJ138 during the uptake phase. Corresponding absorbed dose values to
parental cell lines (i.e. not transfected with NAT resulting in no active
MIBG uptake and no resulting accumulation phase) are presented for
UVW and EJ138 in Figure 6. As clearly seen, the mean dose received by
these donor lines is relatively small, obtaining a maximum of only 0.23 Gy
for UVW and 0.32 Gy for EJ138 parental lines.
By contrast, dose rate at the initiation of the accumulation phase was
significantly greater through the entire spread of activity calculations
applied. For UVW/NAT cells, mean dose rates ranged from 0.09 to 0.75
Gy/h while EJ138/NAT mean dose rates ranged from 0.07 to 0.78 Gy/h
for the respective range of activity concentrations examined. Total dose
to the donor cells producing the ICCM was calculated using Eq. 1 and
recipient survival fraction data was plotted for both transfected cell lines
(Figure 7; bottom x-axis). For comparison purposes, 60Co data for these
cell lines (Boyd et al. 2006) is also shown (Figure 7; top x-axis).
Both UVW/NAT and EJ138/NAT require a relatively small ICCM
treatment dose to yield a substantial bystander response in recipient cells
Dose calculations for [131I]MIBG induced RIBBE
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FIGURE 6. Plot of recipient surviving fraction (SF) data following ICCM treatment for UVW and
EJ138 Parental donor cell types. All SF data was collected across 6 independent experiments per-
formed in triplicate and represented as mean ± SD (Boyd et al. 2006). 
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compared to that used in 60Co treatment. An initial activity concentration
of 1 MBq/ml yields mean dose to donor cells of 0.2 and 0.15 Gy for
UVW/NAT and EJ138/NAT, increasing with activity concentration and
yielding a maximum mean dose 1.6 and 1.7 Gy for each cell line respec-
tively. It is also evident that both cell lines show a decrease in the rate of
bystander cell death as dose increases and approaches 2 Gy.
M.D. Gow and others
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FIGURE 7. Plot of surviving fraction (SF) data for (A) UVW/NAT and (B) EJ138/NAT recipient cells
treated with ICCM from either [131I]MIBG or 60Co irradiation. All SF data was collected across 6 inde-
pendent experiments performed in triplicate and represented as mean ± SD (Boyd et al. 2006). 
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Comparison of survival fractions for identical mean dose ICCM treatments
from 60Co and [131I]MIBG
Lastly, surviving fractions of identical or nearly identical mean dose
points were examined between 60Co (at a dose rate of 15 Gy/h) and
[131I]MIBG ICCM treatments. Figure 8 provides the comparison of these
ICCM treatments for UVW/NAT (A) and EJ138/NAT (B). Both cell lines
appear to have very similar behaviour compared to their 60Co treated
counterpart. For UVW/NAT cells, 5 MBq/ml [131I]MIBG treatment pro-
vided a 50% increase bystander cell death efficiency at a mean maximum
dose rate during the accumulation phase of 0.47 Gy/h. On the other
hand, EJ138/NAT cells provided a 31% to 40% increase in efficiency at
dose points within 10% of 1 Gy 60Co treatment at mean maximum dose
rates ranging from 0.42 Gy/h to 0.49 Gy/h.
4. DISCUSSION
Targeted radionuclide therapy seeks to deliver cytocidal doses of radi-
ation to malignant foci. This is can be confounded by several factors,
including heterogeneous uptake of radiopharmaceutical. Non-uniform
dose distribution may be overcome, through the use of long–range
β–emitters by exploiting the physical bystander effect, which results from
Dose calculations for [131I]MIBG induced RIBBE
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FIGURE 8. Comparison of surviving fraction (SF) of (A) UVW/NAT and (B) EJ138/NAT [131I]MIBG
data with similar 60Co dose end points. All SF data was collected across 6 independent experiments
performed in triplicate and represented as mean ± SD. * indicates p < 0.05 for difference in SF at the
same dose point. 
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signalling between irradiated and neighbouring non-irradiated cells.
Furthermore, toxicity to untargeted regions of tumors may result from
the production of cytotoxic factors from cells which accumulate radio-
pharmaceutical (Boyd et al. 2006). This effect has been described in a
variety of systems over the last 20 years indicating the existence of RIBBEs
both in vitro and in vivo (Brooks 2004). Such effects are reported follow-
ing both of high – and low – LET irradiations and have been cited as pos-
sibly dependent on a number of factors including cytokine release (Gow
et al. 2010), nitric oxide (Shao et al. 2008), gap – junction communication
(Shao et al. 2003), and reactive oxygen species (ROS) / free radical for-
mation (Azzam et al. 2002).
A limitation of radiopharmaceutical RIBBE experiments presented so
far has been the lack of ability to determine appropriate absorbed dose
levels to donor cells resulting from radiopharmaceutical treatment uti-
lized to create ICCM. As a consequence, recipient surviving fraction, typ-
ically measured against absorbed donor dose, has been compared with
administered radiopharmaceutical activity concentration. This does not
enable a comparative evaluation of internalised radionuclides and exter-
nal beam radiation with respect to their induction of bystander effects.
Therefore, the goal of the current study was to develop a method to cal-
culate absorbed dose to donor cells used in ICCM production following
[131I]MIBG treatment.
One of the first challenges in this study was an accurate and efficient
means to model the source distribution after radiopharmaceutical
uptake. This led to the development of both “homogenous-slab” and
“multi-isoplane” source distributions during the accumulation phase.
The hypothesis was that due to the relatively thinness of the cells adher-
ing to the surface of a culture flask, the “multi-isoplane” model would
provide equivalent calculations for dose rates while being computational
more efficient than the “homogenous-slab” model regardless of symbolic
engine. The data presented in Table 1 confirms the success of this
approach with orders of magnitude in computational efficiency achieved.
Furthermore, the code structure for implementation of the “multi-iso-
plane” model into the overall absorbed dose calculation model allowed it
to be compiled via the MATLAB C-Complier (mcc) something not possi-
ble through utilization of the MuPAD or Maple symbolic engine. This
allowed for creation of a standalone, Windows – based application that
can be utilized for future experiments without the need for acquisition or
personal knowledge of the MATLAB environment. This code base can
also be shared and modified allowing for additional enhancements and
dosimetry modelling within the wider scientific community.
The first surviving fraction behaviour examined was that of the
parental cell lines of UVW and EJ138. In the absence of active uptake of
[131I]MIBG, it was anticipated that a smaller dose and dose rate would
M.D. Gow and others
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result during the uptake phase explaining the lack of bystander cell death
observed. The corresponding calculated dose to the parental cell lines
fits this hypothesis achieving only maximal mean doses of 0.23 and 0.32
Gy for UVW and EJ138 respectively. Even for cell lines whose bystander
effects have been characterized, typical survival fraction drops are rela-
tively small (10-15% from control) using medium transfer protocols for
doses of 0.5 Gy (Ryan et al. 2008, Gow et al. 2008). Thus, the findings sup-
port the predictions of the dosimetry model developed.
Next, absorbed dose values for [131I]MIBG treatments for transfected
UVW/NAT and EJ138/NAT donor cells were examined and compared
with dose delivered by external beam (Figure 7). It was observed that the
rate of bystander cell death decreased as dose increased. Absorbed dose
calculations for [131I]MIBG treatment indicate that ICCM production
never resulted in a cell killing plateau as seen after 2 Gy with external
beam treatment. However, in response to [131I]MIBG treatment, there
was a trend toward a plateau with respect to clonogenic cell kill as treat-
ment dose approached 2 Gy. This finding again supports the validity of
the dosimetry model implemented as similar overall behaviour of the sur-
viving fraction curve would be expected for the same cell lines and for
similar low – LET irradiation and dose values.
While similar trends are apparent in surviving fraction curve behav-
iour, significant differences are also obvious in the magnitude of the
bystander cell death response following [131I]MIBG versus external beam
treatment (Figure 8). Two essential differences in treatment are: (a) radi-
ation type (β – particles versus γ – rays) and (b) dose rate (UVW were sub-
jected to 0.09 Gy/h – 0.75 Gy/h and EJ138 were subjected to 0.07 Gy/h
– 0.78 Gy/h in the form of [131I]MIBG treatment whereas external beam
radiation was delivered at 15 Gy/h). With respect to radiation type, it has
long been recognized in experimental biology that similar LET radiations
do not all have the same effectiveness at inducing cellular damage. Using
human lymphocytes and mouse oocytes, it has been shown that 200 kV x
– rays are two – three times as effective as γ – rays at inducing chromo-
some aberrations (Bond et al. 1978, Edwards et al. 1982) while 60Co γ –
rays have been shown to be three times more effective than 15 MeV elec-
trons utilizing the same end point (Edwards et al. 1982). Experiments by
Sasaki et al. (1989) and Schmid et al. (2002) have also pointed to a high-
er rate of chromosome aberrations by lower LET x – rays relative to high
energy γ – rays. Furthermore, for bystander responses in particular, our
group has indicated a significant difference in bystander cell death by
60Co γ – rays compared with 20 MeV electrons for low, nearly equivalent,
clinical dose rate at high doses (Gow, 2008). Therefore, radiation type
cannot be neglected as potentially playing a role in the observed differ-
ences in bystander cell death.
Dose calculations for [131I]MIBG induced RIBBE
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Low dose rate (LDR) irradiation (0.1 Gy/h to 1 Gy/h) has been
reported to affect multiple biological processes in both normal and
tumour cell types (Gridley et al. 2005) and been discussed as potentially
relevant for radionuclide therapy (Sgouros et al. 2007). Decreases in dose
rate are often associated with sparing effects of direct irradiation (Hall
and Bedford 1964) but have been also shown to invoke a hypersensitivity
in some cell lines leading to an increase in cell death relative to higher
dose rates (i.e. ‘inverse dose-rate effect’) (Mitchell et al. 2002). These
inverse dose-rate effects have been observed in a variety of cell types
(DeWeese et al. 1998, Mitchell et al. 2002, Widel and Przybyszewski 1998)
and have been postulated as to reflect the hyper-radiosensitivity of cell
lines in responses to a small, acute dose (Mitchell et al. 2002). Animal
studies have also illustrated the effectiveness of 131I labelled antibody
treatment and low-dose rate versus high-dose rate exposure in signifi-
cantly decreasing tumour volume (Knox et al. 1990). While the precise
mechanisms underlying LDR effects are not completely defined, they are
clearly complex. Any correlation between LDR and bystander effects is
currently unclear but we cannot exclude the possibility that direct LDR
effects would influence subsequent bystander responses measurable
through the medium transfer protocol. In fact, the evidence presented
here suggests that low dose rates may be a dominant contributing factor
to the observed biological bystander cell death.
Although not directly examined here, the bystander responses seen
in ICCM production with [123I] MIBG and [211At] MABG, high LET radio-
pharmaceuticals are discussed in Boyd et al. (2006). These results indicate
in both cases that a maximum bystander response is reached followed by
a substantial decrease in bystander response resulting in a distinct U –
shaped surviving fraction curve. This phenomenon has also been seen by
our group in normal HPV-G keratinocytes (Gow et al. 2008) and in malig-
nant T98G glioma (Gow et al. 2010). In both the conventional and tar-
geted protocols, the reduction of bystander signal strength to near con-
trol levels following lower dose induced production of significant
bystander cell death was observed. We suggest that in the case of radio-
pharmaceuticals, several contributing factors could be involved including
high LET, relatively short particle range, and extranuclear cell accumula-
tion of these radiopharmaceuticals. Dosimetry models for [123I] MIBG
and [211At] MABG may yield high absorbed dose values at the top end
activity concentrations tested. This offers a plausible explanation for the
observed U – shaped behaviour and is a potential area for further inves-
tigation.
Another point of interest involves whether this model is adaptable or
not for targeted high–LET radiotherapy. To do this would require an ade-
quate dose point kernel (DPK) flexible enough to model via similar
geometries and take into account differing radiation parameters (ex.
M.D. Gow and others
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path length and approximating “infinite” sources). Additionally, the
structure of the DPK may limit utilization of computational efficiencies
created via the multi-isoplane approximation. As such, integrating a high-
LET DPK into our code base, should an adequate model exist today, is
possible and could theoretically extend our results under appropriate cir-
cumstance. Otherwise, more complex mathematical modeling would be
required.
5. CONCLUSION
In this study, a computationally efficient model for determining
absorbed dose values following β–emitting radiopharmaceutical treat-
ment was developed. This model was applied to experimental protocol
outlined by Boyd et al. (2006) and used to provide direct comparison with
gamma radiation from an external beam source. This dosimetry provides
a plausible, quantitative explanation for the absence of a bystander
response in cells which were incapable of active accumulation of radio-
pharmaceutical. An explanation is also provided for the overall behaviour
and shape of surviving fraction curves for NAT transfected recipients
capable of active radiopharmaceutical uptake. The model points to the
possibility of LDR effects as an explanation for the observed increase in
efficiency of bystander cell kill following [131I]MIBG treatment. Through
development of a standalone application for the dosimetry model, fur-
ther investigation of bystander responses induced by targeted radiophar-
maceuticals has been made possible. Identification of RIBBE factors will
aid in the development of novel targeted radiopharmaceutical treatment,
maximizing malignant cell death and sparing normal tissue.
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